Mechanisms and Clinical Trials of Hepatocellular Carcinoma Immunotherapy

Mechanisms and Clinical Trials of Hepatocellular Carcinoma Immunotherapy

Hepatocellular carcinoma (HCC), one of the most common and lethal tumors worldwide, is usually not diagnosed until the disease is advanced, which results in ineffective intervention and unfavorable prognosis. Small molecule targeted drugs of HCC, such as sorafenib, provided only about 2.8 months of...

Full description

Bibliographic Details
Main Authors: Shao-Li Huang, Yu-Ming Wang, Quan-Yue Wang, Guang-Gui Feng, Fu-Qing Wu, Liu-Ming Yang, Xi-He Zhang, Hong-Wu Xin
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-07-01
Series:Frontiers in Genetics
Subjects:
hepatocellular carcinoma
immunotherapy
bispecific T-cell Engagers
bispecific antibody
aptamer
vascular endothelial growth factor (VEGF)
Online Access:https://www.frontiersin.org/articles/10.3389/fgene.2021.691391/full

Internet

https://www.frontiersin.org/articles/10.3389/fgene.2021.691391/full

Similar Items